Results 21 to 30 of about 44,703 (257)

Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma. [PDF]

PLoS ONE, 2014
OBJECTIVE: To evaluate the association of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma (PTC).
Ah Young Park, Eun Ju Son, Jeong-Ah Kim, Ji Hyun Youk, Yun Joo Park, Cheong Soo Park, Hang Seok Chang   +6 more
doaj   +1 more source

Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. [PDF]

, 2017
An excessive requirement for methionine termed methionine dependence, appears to be a general metabolic defect in cancer. We have previously shown that cancer-cell growth can be selectively arrested by methionine deprivation such as with recombinant ...
Chmielowski, Bartosz, Dry, Sarah M, Eilber, Fritz C, Han, Qinghong, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Shukuan, Li, Yunfeng, Miyake, Kentaro, Murakami, Takashi, Nelson, Scott D, Russell, Tara A, Tan, Yuying, Unno, Michiaki   +15 more
core   +2 more sources

A multi-center cross-sectional investigation of BRAF V600E mutation in Ameloblastoma [PDF]

PeerJ
Background B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutation stands as a pivotal genetic alteration strongly associated with several neoplasms and contributes significantly to their pathogenesis as well as potential targeted treatment ...
Khin Mya Tun, Puangwan Lapthanasupkul, Anak Iamaroon, Wacharaporn Thosaporn, Poramaporn Klanrit, Sompid Kintarak, Siwaporn Thanasan, Natchalee Srimaneekarn, Nakarin Kitkumthorn   +8 more
doaj   +2 more sources

Targeting Oncogenic BRAF: Past, Present, and Future. [PDF]

, 2019
Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a "precision medicine" paradigm to diagnose and treat BRAF-driven tumors.
Bivona, Trever G, Wu, Wei, Zaman, Aubhishek   +2 more
core   +1 more source

The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population

International Journal of Endocrinology, 2022
Background. The BRAF V600E mutation is an important genetic event in papillary thyroid cancer (PTC). This study aimed to provide additional information regarding the association of the BRAF V600E mutation with PTC prognosis. Methods.
Ziheng Ye, Xiaotian Xia, Peipei Xu, Wenfei Liu, Shoufei Wang, Youben Fan, Minggao Guo   +6 more
doaj   +1 more source

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. [PDF]

, 2017
BackgroundMetastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest growing global incidence rate of all malignancies.
Ahuja, Amit, Chen, Lei, Daud, Adil, Gill, Japinder, Kamra, Sheily   +4 more
core   +2 more sources

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma [PDF]

British Journal of Cancer, 2013
To examine the association between level and patterns of baseline intra-tumoural BRAF(V600E) protein expression and clinical outcome of BRAF(V600E) melanoma patients treated with selective BRAF inhibitors.Fifty-eight BRAF(V600E) metastatic melanoma patients treated with dabrafenib or vemurafenib on clinical trials had pre-treatment tumour BRAF(V600E ...
Wilmott, J S, Menzies, A M, Haydu, L E, Capper, D, Preusser, M, Zhang, Y E, Thompson, J F, Kefford, R F, von Deimling, A, Scolyer, R A, Long, G V   +10 more
openaire   +2 more sources

BRAF V600E-Positive Congenital Multisite Langerhans Cell Histiocytosis [PDF]

Cureus, 2020
Congenital Langerhans cell histiocytosis (LCH) usually manifests as a disease limited to the skin, with self-healing characteristics; however, in some cases, it may be a more severe entity, with multisystemic expression and poor prognosis. We present the case of a patient diagnosed with multisystemic congenital LCH, with the presence of the BRAF V600E ...
Prada Avella, Maria Camila, Suárez, Amaranto, Contreras, Sharon, Calderon, Alejandra   +3 more
openaire   +2 more sources

BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.

PLoS ONE, 2020
Analyzing the mutational load of driver mutations in melanoma could provide valuable information regarding its progression. We aimed at analyzing the heterogeneity of mutational load of BRAF V600E in biopsies of melanoma patients of different stages, and
Arrate Sevilla, M Celia Morales, Pilar A Ezkurra, Javier Rasero, Verónica Velasco, Goikoane Cancho-Galan, Ana Sánchez-Diez, Karmele Mujika, Cristina Penas, Isabel Smith, Aintzane Asumendi, Jesús M Cortés, Maria Dolores Boyano, Santos Alonso   +13 more
doaj   +1 more source

Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. [PDF]

PLoS ONE, 2009
A CpG island methylator phenotype (CIMP) is displayed by a distinct subset of colorectal cancers with a high frequency of DNA hypermethylation in a specific group of CpG islands. Recent studies have shown that an activating mutation of BRAF (BRAF(V600E))
Toshinori Hinoue, Daniel J Weisenberger, Fei Pan, Mihaela Campan, Myungjin Kim, Joanne Young, Vicki L Whitehall, Barbara A Leggett, Peter W Laird   +8 more
doaj   +1 more source